Recent News
The Lancet on the PAF AbbVie case: AbbVie to face potentially groundbreaking case over Humira
The Lancet interviewed the chair of the Pharmaceutical Accountability Foundation (Wilbert Bannenberg) about the recent verdict of the Amsterdam Court moving the case to the...
PRESS RELEASE: Lawsuit against AbbVie for abuse of economic dominance and violation of human rights moves to substantive phase
AbbVie's Humira pricing policy drained up to €1.2 billion from the Dutch healthcare system
AMSTERDAM, NETHERLANDS: Today the Amsterdam District Court ruled that the lawsuit filed...
The Pharmaceutical Accountability Foundation faces AbbVie in Court for the first time in its Humira pricing case
AMSTERDAM, THE NETHERLANDS: In February of 2023, the Pharmaceutical Accountability Foundation (PAF) brought a lawsuit against the company on the grounds that AbbVie had abused...
“Six billion people have access to medicines today. So a lot has been achieved”
Wilbert Bannenberg, Chair of the Pharmaceutical Accountability Foundation, was interviewed by the Volkskrant on his life's work: promoting global equitable access to medicines. The article...
AbbVie tries to escape accountability for overcharging the Dutch healthcare system by 1.2 billion Euros
AMSTERDAM, THE NETHERLANDS: In February of 2023, the Pharmaceutical Accountability Foundation (PAF) brought a lawsuit against the company on the grounds that AbbVie had abused...
The Pharmaceutical Accountability Foundation’s case against AbbVie: The Facts
Version 15 November 2023
About Adalimumab/Humira and pricing issues
AbbVie’s blockbuster drug Adalimumab (brand name: Humira) for the treatment of rheumatoid arthritis is one of the best...